Viatris and Idorsia Enter Into Significant Global Research a

Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue PotentialIncludes Future Optionality to Expand...

Related Keywords

Hyderabad , Andhra Pradesh , India , Switzerland , New York , United States , South Korea , Shanghai , China , New York University , Columbia University , Japan , America , Swiss , Scotta Smith , Anca Askanase , Jean Paul Clozel , Philippe Martin , Deepakl Bhatt , Linkedin , Idorsia Ltd , Lupus Center , Viatris Inc , Swiss Exchange , Nasdaq , Youtube , Prnewswire Viatris Inc , Instagram , Productive Drug Development Team , York University , Exchange Commission , Twitter , Expands Viatri Portfolio , Innovative Assets , Immediately Adding Two Phase , Both With Blockbuster Revenue , Future Optionality , Expand Collaboration With Additional Innovative , Viatri Financial Strength , Worldwide Operational Infrastructure Withidorsia , Highly Productive Drug Development Team , Structure Reinforces Viatri Disciplined Approach , Announces Rd Event , Held March , Chief Rd Officer Philippe Martin , Paul Clozel , Global Healthcare , Mount Sinai , Rheumatology Clinical , Selatogrel Outcome Study , Acute Myocardial Infarction , Special Protocol Assessment , North America , Private Securities Litigation Reform Act , Fair Disclosure , Markets ,